Navigation Links
EDARBYCLOR (azilsartan medoxomil and chlorthalidone) Now Available in U.S. Pharmacies for Patients with Hypertension
Date:2/6/2012

hypertension patients are not at their blood pressure targets, putting them at increased cardiovascular risk," said Douglas Cole, president, Takeda Pharmaceuticals U.S.A., Inc. "We're pleased to bring EDARBYCLOR to market and expand the EDARBI family of products to help appropriate patients with hypertension work towards reaching their blood pressure goals."

About Hypertension
Hypertension, or high blood pressure, is a chronic medical condition in which blood pressure is elevated to levels of 140 mm Hg or greater systolic and/or 90 mm Hg or greater diastolic. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Control of high blood pressure should be part of comprehensive cardiovascular risk management including, as appropriate, lipid control, management of diabetes, prevention of blood clots, smoking cessation, exercise and limited sodium intake.

Hypertension impacts approximately 76 million Americans, or nearly one in three adults. It is estimated that nearly one billion people are affected by hypertension worldwide, and this figure is predicted to increase to 1.5 billion by 2025. Hypertension typically has no symptoms. Adults of all ages and backgrounds can develop hypertension; however, the risk of developing the condition increases with age, with more than half of people over age 60 affected. Hypertension is also costly to the nation's health care system. The American Heart Association recently estimated that direct and indirect expenses associated with hypertension cost the nation more than $73 billion in 2009.

About EDARBI and EDARBYCLOR
EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) developed by Takeda for the treatment of hypertension to lower blood pressure in adults. EDARBI lowers blood pressure b
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension
2. EDARBI (azilsartan medoxomil), Now Available in U.S. Pharmacies for Patients With Hypertension
3. FDA Approves EDARBI (azilsartan medoxomil) for the Treatment of Hypertension
4. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
5. New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure
6. New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
7. NHS Makes £200 Non-Drug Hypertension Treatment Device Available on Prescription
8. PuraMed BioScience, Inc. Announces LipiGesic®M, Their Unique Migraine Treatment, is Now Available for Purchase at CVS, the 2nd Largest Drug Chain in the United States
9. Nearly 9 Million Kaiser Permanente Health Records Securely Available on Mobile Devices
10. Edgemont - New Fluoxetine Tablets, 60 mg Now Available
11. Simbionix Comprehensive Medical Simulators now Available in Additional Languages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015 Hill-Rom,s recent ... $2 billion in cash and stock means the ... market, according to Kalorama Information. The healthcare market ... the medical device and advanced wound care markets, ... beds, patient lifting devices, and other healthcare equipment. ...
(Date:7/7/2015)... , July 7, 2015  Shareholder rights law ... a federal securities fraud class action complaint was ... Southern District of California.  The complaint alleges that ... CLDN ) violated the Securities Exchange Act of ... 2015, by making materially false and misleading statements ...
(Date:7/7/2015)... 7, 2015 According to ... Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, ... Alpha Emitters, Brachytherapy - Y-90), by Application (Oncology, ... by MarketsandMarkets, this report studies the global Nuclear ... to 2020. This market is expected to reach ...
Breaking Medicine Technology:Kalorama: Hill-Rom Enters Monitoring Market with Welch Allyn Purchase 2Kalorama: Hill-Rom Enters Monitoring Market with Welch Allyn Purchase 3Robbins Arroyo LLP: Celladon Corporation (CLDN) Misled Shareholders According to a Recently Filed Class Action 2Robbins Arroyo LLP: Celladon Corporation (CLDN) Misled Shareholders According to a Recently Filed Class Action 3Nuclear Medicine/Radiopharmaceuticals Market Worth $6.96 Billion by 2020 2Nuclear Medicine/Radiopharmaceuticals Market Worth $6.96 Billion by 2020 3Nuclear Medicine/Radiopharmaceuticals Market Worth $6.96 Billion by 2020 4
(Date:7/7/2015)... ... July 07, 2015 , ... Leading healthcare consulting firm ... as Senior Vice President, heading the firm’s Healthcare Advisory Services division. , Mr. ... to healthcare providers’ needs in ways that strengthen their position in the marketplace. ...
(Date:7/7/2015)... ... July 07, 2015 , ... Difass USA, a modern supplement brand committed to ... days at work is knowing that there is hopefully a vacation to look forward ... as imagined. Planning for a vacation can be quite stressful, and it’s difficult sometimes ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... today that the two firms have merged to form Camber Collective. Camber ... biopharma sectors. The merger combines SwitchPoint’s strategy consulting expertise with Hope Consulting’s ...
(Date:7/7/2015)... , ... July 07, 2015 , ... Quadrino Law Group ... Road, Suite 304, Melville, New York 11747. The new facility is a state ... and rail lines. , Richard Quadrino, the firm's CEO and founder, said, "We are ...
(Date:7/7/2015)... ... July 07, 2015 , ... At the end of June Pacific Prime Renewals team in ... . This initiative, spearheaded by the Renewals Manager, Danielle Cotton, aims to not only reduce ... On this initiative Cotton explained, “We send anything between 300 and 600 pieces of paper ...
Breaking Medicine News(10 mins):Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 2Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 3Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 2Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 3Health News:SwitchPoint and Hope Consulting Have Merged to Form Camber Collective 2Health News:Pacific Prime Hong Kong Renewals Team Starts Push to go Green 2
... Zoo & PPG Aquarium for May 28, PITTSBURGH, May ... Plan, is the Pennsylvania state sponsor for the 15th annual,National ... "Fitness ...,A Lifetime Investment.", National Senior Health & Fitness ... for Life will serve as host for three events in,Pennsylvania. ...
... by the American Academy of Child and ... and Adults with,Attention-Deficit/Hyperactivity Disorder and the National ... 16 The American Heart,Association released on ... and monitoring of children receiving drugs for ...
... key to decreasing the spread of cancer in women ... Washington University School of Medicine in St. Louis. ... metastasis, of breast cancer. Scientists here found that women ... a bone strengthening drug were less likely to have ...
... An AIDS Vaccine is Possible and,Still Urgently Needed, ... of HIV, the world has made considerable advances in ... about HIV,perhaps more than any other pathogen, and have ... diseases combined. But this progress is not,enough. While it ...
... May 16 /Xinhua-PRNewswire-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: BJGP ) ... that the Company,will present at the following conferences:, ... cities in China. David Gao, ... scheduled to present on May 19, 2008, ...
... Researchers from The University of Texas M. D. Anderson ... human leukemia cells in mice using natural killer (NK) ... Ph.D., assistant professor of pediatrics from the Children,s Cancer ... method for expanding the number of NK cells from ...
Cached Medicine News:Health News:UPMC for Life is Pennsylvania Sponsor for National Senior Health & Fitness Day 2Health News:American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD 2Health News:Bone drug could help prevent the spread of breast cancer 2Health News:World AIDS Vaccine Day 2008 2Health News:World AIDS Vaccine Day 2008 3Health News:World AIDS Vaccine Day 2008 4Health News:BMP Sunstone Announces Participation in May Investor Conferences 2Health News:Researchers expand natural killer cells in cord blood to fight leukemia 2
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Legionella provides rapid, accurate results that aid in the presumptive diagnosis of Legionella infection (Legionnaires' Disease)....
... The Trinity Biotech Captia™ ... Assay (ELISA) is intended for ... antibodies (IgG and IgM) to ... in serum from patients with ...
The GoodKnight® 425 Bi-Level® device is suitable for travel and includes features such as automatic altitude compensation, optional cigarette lighter adapter and portable battery pack...
Medicine Products: